Decheng Capital’s Cytokinetics CYTK Stock Holding History

Decheng Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$4.02M	–	27
2025 Q1	$4.02M	Hold	100,000	–	–	1.13%	15
2024 Q4	$4.7M	Buy	100,000 +5,957	+6%	+$309K	1.01%	19
2024 Q3	$4.97M	Hold	94,043	–	–	1.18%	14
2024 Q2	$5.1M	Hold	94,043	–	–	1.56%	14
2024 Q1	$6.59M	Buy	+94,043	New	+$7.27M	0.88%	14

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Decheng Capital's CYTK Position: Q2 2025 in Review

Decheng Capital sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 100,000 shares — an estimated $4.02M sold.

Decheng Capital first reported a position in CYTK in Q1 2024 and held it in 5 quarters. The position peaked at $6.59M in Q1 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Decheng Capital reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Decheng Capital sold 100,000 Cytokinetics shares in Q2 2025, an estimated $4.02M.
Decheng Capital first reported a position in Cytokinetics in Q1 2024 and held it in 5 quarters.
Decheng Capital's Cytokinetics position peaked at $6.59M in Q1 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Decheng Capital's 13F filing for Q2 2025, filed 13 Aug 2025.